THE EVOLVING ROLE OF RADIOTHERAPY IN EARLY STAGE HODGKIN’S LYMPHOMA by Umberto, Ricardi et al.
See	discussions,	stats,	and	author	profiles	for	this	publication	at:	https://www.researchgate.net/publication/263354083
The	Evolving	Role	of	Radiotherapy	in	Early
Stage	Hodgkin’s	Lymphoma
Article		in		Mediterranean	Journal	of	Hematology	and	Infectious	Diseases	·	January	2014
DOI:	10.4084/MJHID.2014.035	·	Source:	PubMed
CITATIONS
0
READS
53
4	authors,	including:
Umberto	Ricardi
Università	degli	Studi	di	Torino
313	PUBLICATIONS			2,565	CITATIONS			
SEE	PROFILE
Andrea	Riccardo	Filippi
Università	degli	Studi	di	Torino
91	PUBLICATIONS			786	CITATIONS			
SEE	PROFILE
Pierfrancesco	Franco
Università	degli	Studi	di	Torino
124	PUBLICATIONS			686	CITATIONS			
SEE	PROFILE
All	content	following	this	page	was	uploaded	by	Pierfrancesco	Franco	on	27	June	2014.
The	user	has	requested	enhancement	of	the	downloaded	file.	All	in-text	references	underlined	in	blue
are	linked	to	publications	on	ResearchGate,	letting	you	access	and	read	them	immediately.
Mediterr J Hematol Infect Dis 2014; 6; Open Journal System  
  
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES 
www.mjhid.org ISSN 2035-3006 
 
 
Review Article 
 
The Evolving Role of Radiotherapy in Early Stage Hodgkin’s Lymphoma. 
 
Umberto Ricardi, Andrea Riccardo Filippi*, Cristina Piva and Pierfrancesco Franco 
 
Department of Oncology, Radiation Oncology, University of Torino, Torino, Italy 
 
Correspondence to: Andrea Riccardo Filippi, MD. Department of Oncology, Radiation Oncology, University of 
Torino. Via Genova 3, 10126 Torino, Italy. Tel. +39 011 6705352, Fax. + 39 011 6336614.  
E-mail: andreariccardo.filippi@unito.it 
 
Competing interests: The authors have declared that no competing interests exist. 
 
Published: June 1, 2014 
Received: March 2, 2014 
Accepted: April 27, 2014 
Citation: Mediterr J Hematol Infect Dis 2014, 6(1): e2014035, DOI: 10.4084/MJHID.2014.035 
This article is available from: http://www.mjhid.org/article/view/12902  
This is an Open Access article distributed under the terms of the Creative Commons Attribution License 
(http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited.  
  
Abstract. Radiation therapy has a key role in the combined modality treatment of early-stage 
Hodgkin’s Lymphoma (HL). Nevertheless, late toxicity still remains an issue.   A modern approach 
in HL radiotherapy includes  lower doses and smaller fields, together with the implementation of 
sophisticated and dedicated delivery techniques. Aim of the present review is to discuss the current 
role of radiotherapy and its potential future developments, with a focus on major clinical trials, 
technological advances  and their repercussion in the clinical management of HL patients. 
Introduction. In the era of modern chemotherapy and 
new highly effective targeted agents, many clinicians 
may perceive external beam radiotherapy (RT) as an 
old-fashioned treatment for Hodgkin’s Lymphoma 
(HL). In fact, the initial demonstration of X-ray 
effectiveness in HL was made a century ago,
1
 while the 
first clinical results on disease control and survival 
have been published in 1935 and 1950.
2,3
 However, we 
are still using this powerful single agent, albeit in a 
very different way than in early years. For decades 
Extended Fields Radiotherapy (EF-RT) has been 
considered the standard treatment for early stage HL, 
on the basis of the ground-breaking work published by 
Kaplan in 1968.
4
 It has later become evident that EFRT 
was associated with a high risk of treatment-related 
complications, mainly represented by heart diseases, 
secondary cancers and endocrine dysfunctions.
5,6,7
 
Concomitantly, chemotherapy has been shown to 
improve results when combined with radiation in early 
stages.
8
 A large number of subsequent randomized 
controlled trials, designed and conducted over the last 
20 years, lead to re-think the role of RT, modifying its 
indications and use and questioning its incorporation in 
such combinations because of concerns about late 
toxicity. The technological “revolution,” occurred over 
the last 15 years in Radiation Oncology, made also 
possible a different technical approach to HL, by 
applying the new concepts of high-precision image-
guided and intensity-modulated RT, even when  doses 
in the range of 20-30 Gy were delivering.  
Aim of this review is:  
a) to summarize and discuss the main changes and 
the current role of RT in the treatment for HL, and  
b) to delineate the present and future research paths 
in RT, focused on maintaining efficacy while 
minimizing late effects on long-term survivors.  
 
Overview of Clinical Trials. The initial use of RT was 
based upon extensive treatment volumes covering both 
involved and uninvolved lymphatic sites. For the most 
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common presentations in early stages, for example, 
neck and mediastinum, this approach consisted of sub-
total nodal irradiation (STNI), to the dose of 40-44 Gy. 
The results obtained in the time lapse 1962-1984 by the 
Stanford group in early stages with EFRT show 
complete remission rates of 100% and recurrence-free 
survival (RFS) rates of 80% in stages IA, IIA and IIB 
without large mediastinal tumors.
9
 In the eighties 
(1988–1994), the German Hodgkin Study Group 
(GHSG) designed the HD4 trial, one of first studies to 
address a specific RT-related question. The major aim 
of HD4 was to show whether the radiation dose to the 
non-involved lymphatic regions could be reduced 
while maintaining an effective tumor control. Patients 
with early stage HL without risk factors (large 
mediastinal mass, extra-nodal extension, massive 
spleen involvement, > 3 lymph node areas, high 
Erythrocyte Sedimentation Rate) were randomized 
between 40 Gy EF-RT (arm A) and 30 Gy EF-RT plus 
additional 10 Gy to the Involved Field (IF) region (arm 
B). Results showed no statistically significant 
differences in RFS and overall survival (OS) between 
the 2 treatment arms, but the overall recurrence rate 
approached 20%. As relapsing patients underwent an 
effective salvage therapy, RFS after 7 years came up to 
80%, with an overall survival rate of 93%.
10
 For this 
study, GHSG promoted the creation of a task force for 
quality assurance (QA). For all patients enrolled in the 
study, a treatment plan was given by the radiotherapy 
reference Centre based on the documentation of the 
disease extension on case report forms. After 
completion of EF-RT, an expert panel analyzed 
simulation and verification films of every individual 
patient, as well as treatment data. This retrospective 
quality control study showed that deviations of 
radiation treatment portals and radiation doses from 
prospective treatment prescriptions were unfavorable 
prognostic factors.
11
 Second generation of trials 
compared, both in favorable and unfavorable 
presentations, EFRT vs. IFRT in combination with 
chemotherapy. Very valuable data came from these 
studies, which completely changed the previous 
treatment paradigm, by showing that the combination 
of systemic agents and RT was superior to EFRT 
alone, both in terms of disease control and inferior 
toxicity. Moreover, these trials demonstrated that, 
when combined with chemotherapy, RT could be 
safely reduced to the IF region.
12,13,14
 This evolution 
also led to an initial important reduction of late 
toxicity, as described by the 2005 Cochrane review 
focused on the therapy of early stage HL and second 
cancer risks.
15
 At the end of the nineties, a decisive step 
towards a further reduction of the therapeutic burden 
was made by GHSG in 2 key studies, the HD10 ad 
HD11 (1998–2002). In these trials, irradiation was 
performed as IF-RT only in all treatment arms, with 
reduced total doses in combination with different 
chemotherapy schedules. The whole treatment strategy 
was based upon a proper selection of patients by 
known prognostic factors.  In HD10, stage I-II patients 
without risk factors (no bulky disease, less than 3 
involved sites, low ESR values) were randomized in a 
four-arm study between an IF-RT dose of 30 Gy vs. 20 
Gy and 2 vs. 4 cycles of ABVD. Meanwhile, an 
extensive quality assurance program has been made in 
order to ensure that IF-RT was performed exactly 
according to the RT-prescriptions of the protocol. 
 Results of HD10 were published in 2010:
16
 the 2 
chemotherapy regimens did not differ significantly 
with respect to freedom from treatment failure (FFTF) 
(p=0.39) or OS (P=0.61). At 5 years, the rates of FFTF 
were 93.0% (95% confidence interval [CI], 90.5 to 
94.8) with the four-cycle ABVD regimen and 91.1% 
(95% CI, 88.3 to 93.2) with the two-cycle regimen.  
When the effects of 20-Gy and 30-Gy doses of 
radiation therapy were compared, there were also no 
significant differences in FFTF or OS (p=0.61). HD10 
showed that the treatment with two cycles of ABVD 
followed by 20 Gy of IF-RT was equally effective, and 
less toxic (acute toxicity), compared to treatment with 
4 cycles of ABVD followed by 30 Gy IF-RT. 
Therefore, 2 ABVD cycles plus IFRT 20 Gy emerged 
as the standard treatment worldwide for low risk 
patients. The GHSG HD11 trial,
17
 in patients with 
unfavorable early stage disease presentation (bulky 
disease, multiple involved sites, high ESR values), 
showed that, after 4 cycles of BEACOPP, IF-RT 20 Gy 
was not inferior to 30 Gy, whereas inferiority of 20 Gy 
cannot be excluded after 4 cycles of ABVD. 
At the same time, other research groups tested a 
chemotherapy alone strategy in early stage HL, based 
on similar criteria for patients’ selection (low risk of 
treatment failure). Some of these studies were 
conducted on children and/or young adults. The CCG 
5942 trial showed inferior 10-year event-free survival 
for the no RT versus the RT arm (82.9% vs. 91.2%, 
p=0.004). After stratification for risk factors, a 
significant difference was evident for the low risk 
patients (89.1% vs. 100%, P=0.001), but not for the 
intermediate and high-risk groups (78.0% vs. 84% and 
79.9% vs. 88.5%, respectively).
18
 Conversely, the 
GPOH-HD95 trial showed that the omission of RT was 
safe only for low-risk patients with complete response 
after chemotherapy (PFS of 96.8% versus 93.6%, 
p=0.42), whereas this strategy was not proven to be 
safe for the intermediate and the high risk groups (PFS 
69.1% vs. 92.4%, p<0.001 and 82.3% vs. 90.7%, 
p=0.08, respectively).
19
 In adults, the largest study to 
compare chemotherapy alone with combined modality 
therapy was the intergroup HD.6 study (NCIC), 
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designed with the aim of comparing chemotherapy 
alone (4-6 ABVD cycles) to RT only or with 2 ABVD 
cycles (according to risk groups), with subtotal nodal 
irradiation 35 Gy.
20
 An obvious critical point is that 
STNI is no more part of current treatments protocols, 
and thus a direct comparison on late toxicity versus 
chemotherapy alone is unbalanced. In 2010, Herbst et 
al published a systematic review with meta-analysis of 
randomized controlled trials comparing chemotherapy 
alone with CMT in patients with early stage Hodgkin’s 
lymphoma with respect to response rate, tumor control 
and overall survival. Five randomized controlled trials 
involving 1,245 patients were included. The hazard 
ratio was 0.41 for tumor control and 0.40 for OS for 
patients receiving CMT compared to chemotherapy 
alone.
21
 
The results of these studies raised an important 
debate in the scientific community, still ongoing at 
present. An individual patient meta-analysis was 
recently undertaken to compare HD10 and HD11 
results with HD.6 study. On 406 patients who fulfilled 
the eligibility criteria, combined modality therapy was 
shown to give better time to progression (HR=0.44); 
PFS was superior but without reaching statistical 
significance, and overall survival superimposable. 
Remarkably, the difference between the two treatments 
was particularly evident among patients in partial 
remission after chemotherapy.
22
 
The following logical step was to try to better select 
patients at lower/higher risk of relapse, and 
consequently to better adapt the use of consolidation 
RT. FDG-PET emerged as a powerful tool to predict 
early chemo-sensitivity in advanced stages,
23
 and was 
consequently introduced in early stages to stratify 
patients with different response to chemotherapy. In 
these studies, functional imaging was used to modulate 
therapy, comparing chemotherapy alone strategy to 
combined modality treatment, consisting of a brief 
chemotherapy followed by low-dose IF-RT, in patients 
achieving complete remission at FDG-PET. Three 
major trials were designed over the last years according 
to this principle, the H10 trial (EORTC/GELA/FIL), 
the GHSG HD16 trial and the UK NCRI RAPID trial. 
In all studies, a panel of expert Nuclear Medicine 
physicians reviewed FDG-PET imaging results. H10 
compared ABVD + RT vs. an experimental arm where 
the treatment was driven by interim (after 2 ABVD 
cycles) FDG-PET results. Notably, H10 represented a 
very innovative step for radiotherapy, introducing the 
new concept of “Involved Node Radiotherapy” (IN-
RT), a further reduction of radiation volumes on the 
basis of pre- and post-chemotherapy imaging.
24
 
Patients with favorable presentations according to 
EORTC criteria were randomized to ABVD x 3 + IN-
RT 30 Gy vs. ABVD x 2 and, if PET negative, 2 more 
ABVD cycles (chemotherapy alone). This trial is now 
closed, and the final results will be available within 
next 2 years. An independent data monitoring 
committee advised to stop the chemotherapy alone arm 
due to an excess number of relapses (in both favorable 
and unfavorable arms).
25
 This decision was deeply 
discussed, as probably a difference in failure-free 
survival between the 2 arms (the primary endpoint for 
non-inferiority), was to be accounted in the statistical 
design at the beginning, even in patients in metabolic 
complete response. Overall Survival is expected to be 
the same for both arms after adequate salvage therapy. 
The ongoing GHSG HD16 trial has more 
“contemporary” design with regards to RT doses and 
compares, in favorable patients (according to GHSG 
criteria), a standard arm consisting of 2 ABVD cycles 
followed by 20 Gy IF-RT to a PET-guided 
experimental arm consisting of 2 ABVD and 
observation (if negative) or IF-RT 20 Gy (if positive). 
The purely RT-related question on the potential 
equivalence of IF-RT and IN-RT is being investigated 
in a parallel trial, the GHSG HD17.
26
 
In UK NCRI RAPID trial, low-risk patients with a 
PET negative finding after 3 ABVD cycles were 
randomized either to 30 Gy IF-RT or to observation 
only. Patients with a positive PET were treated with 
one more ABVD cycle plus 30 Gy IF-RT. Preliminary 
findings were disclosed firstly at the 2012 ASH 
meeting
27
 and then, in updated version, at the ISHL 
2013 meeting in Cologne.
28
 The number of events 
needed to complete the statistical analysis is not 
reached yet, but results suggest, as expected, slightly 
inferior RFS for chemotherapy alone in comparison 
with chemo-radiotherapy in PET negative patients, 
representing 75% of patients using a prudential cut-off 
for positivity at Deauville’s score 3 (3-year PFS: 90.8% 
vs. 94.5%, per protocol). PET positive patients had 
86.2% PFS rate. OS was equivalent, with most 
relapsing patients receiving efficient salvage therapies 
(not always including ASCT). Table 1 summarizes the 
results of major clinical trials with radiotherapy-related 
endpoints in early stage HL. 
The impact of such studies on the current role of RT 
outside clinical trials is difficult to evaluate; however, 
data suggest that the omission of RT, even in selected 
patients, may lead to inferior relapse-free survival 
rates. On the other side, the entity of the difference is 
small and overall survival rates are probably similar. 
Nevertheless, the use of early PET findings to guide 
therapy outside clinical trials is generally considered 
not appropriate, for two main reasons: an unclear role 
as a prognostic marker in early stage in comparison 
with advanced stages, with controversial retrospective 
findings,
29,30
 and the need to have a strict quality 
control on images interpretation in daily clinical
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Table 1. Summary of clinical trials investigating for radiotherapy-related endpoints. 
Study N 
Median 
follow-up, mo 
Treatment OS, % P 
FFTF, EFS, 
FFP, PFS, % 
P 
GHSG (HD4)10 376 86 EFRT 40 Gy 
EFRT 30 Gy 
91 at 7 yr 
96 at 7 yr 
NS 78 at 7 yr 
83 at 7 yr 
NS 
Istituto Nazionale 
Tumori12 
136 116 ABVD x 4 + STNI 
ABVD x 4 + IFRT 
96 at 12 yr 
94 at 12 yr 
NS 93 at 12 yr 
94 at 12 yr 
NS 
GHSG (HD8)13 1064 54 COPP/ABVD x 2 + EFRT 
COPP/ABVD x 2 + IFRT 
90.8 at 5 yr 
92.4 at 5 yr 
NS 85.8 at 5 yr 
84.2 at 5 yr 
NS 
EORTC (H8)14 
Favorable 
 
 
 
Unfavorable 
 
542 
 
 
 
996 
 
92 
 
STNI 
MOPP-ABV x 3 + IFRT 
 
 
MOPP-ABV x 6 + IFRT 
MOPP-ABV x 4 + IFRT 
MOPP-ABV x 4 + STNI 
 
92 at 10 yr 
97 at 10 yr 
 
 
88 at 10 yr 
85 at 10 yr 
84 at 10 yr 
 
.001 
 
 
 
NS 
 
74 at 5 yr 
98 at 5 yr 
 
 
84 at 5 yr 
88 at 5 yr 
87 at 5 yr 
 
< .001 
 
 
 
NS 
GHSG (HD10)16 1370 90 ABVD x 2 + IFRT 20 Gy 
ABVD x 2 + IFRT 30 Gy 
ABVD x 4 + IFRT 20 Gy 
ABVD x 4 + IFRT 30 Gy 
95 at 8 yr 
94 at 8 yr 
95 at 8 yr 
94 at 8 yr 
NS 86 at 8 yr 
86 at 8 yr 
90 at 8 yr 
87 at 8 yr 
NS 
GHSG (HD11)17 1395 91 ABVD x 4 + IFRT 20 Gy 
ABVD x 4 + IFRT 30 Gy 
BEACOPPbase x 4 + IFRT 20 Gy 
BEACOPPbase x 4 + IFRT 30 Gy 
94 at 5 yr 
94 at 5 yr 
95 at 5 yr 
95 at 5 yr 
NS 81 at 5 yr 
85 at 5 yr 
87 at 5 yr 
87 at 5 yr 
 
.02 
CCG (5942)18 826 91 COPP/ABVD x 4 or COPP/ABV x 6 
or 6 intensified cycles + IFRT 
COPP/ABVD x 4 or COPP/ABV x 6 
or 6 intensified cycles + NFT 
97.1 at 10 
yr 
 
95.9 at 10 
yr 
.05 91.2 at 10 yr 
 
82.9 at 10 yr 
 
.004 
GPOH (HD95)19 925 120 OPPA/OEPA x 2 
OPPA/OEPA x 2 + RT if PR 
OPPA/OEPA x 2 + COPP x 2 
OPPA/OEPA x 2 + COPP x 2 + RT if 
PR 
OPPA/OEPA x 2 + COPP x 4 
OPPA/OEPA x 2 + COPP x 4 + RT if 
PR 
98.5 at 10 
yr 
98.7 at  10 
yr 
97.7 at 10 
yr 
98.1 at 10 
yr 
100 at 10 
yr 
95.3 at 10 
yr 
NS 
 
NS 
 
NS 
97.0 at 10 yr 
92.2 at 10 yr 
68.5 at 10 yr 
91.4 at 10 yr 
82.6 at 10 yr 
88.7 at 10 yr 
NS 
 
<.001 
 
NS 
NCIC/ECOG 
(HD.6)20 
399 50 ABVD x 4-6 
ABVD x 2 + STNI 
96 at 5 yr 
94 at 5 yr 
NS 87 at 5 yr 
93 at 5 yr 
.006 
EORTC/LYSA/FI
L (H10 interim 
analysis)25 
Favorable 
 
 
 
 
Unfavorable 
 
 
 
444 
 
 
 
 
693 
 
 
 
13 
 
 
 
ABVD x 3 + INRT 
ABVD x 4 
ABVD x 2 + BEACOPPesc x 2 + 
INRT 
 
 
ABVD x 4 + INRT 
ABVD x 6 
ABVD x 2 + BEACOPP x 2 + INRT 
 
 
 
/ 
/ 
 
 
 
/ 
/ 
  
 
 
100 at 1 yr 
94.3 at 1 yr 
 
 
 
97.28 at 1 yr 
94.7 at 1 yr 
 
 
 
.017 
 
 
 
 
.026 
UK NCRI (RAPID 
interim analysis)27 
420 
PET 
neg. 
48 ABVD x 3 + NFT 
ABVD x 3 + IFRT 
/ 
/ 
 90.8 at 3 yr 
94.5 at 3 yr 
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routine (in all trials, PET images were centrally 
reviewed by a panel of nuclear medicine experts). 
 
Innovations in Radiotherapy and Strategies to 
Minimize Radiation-Induced Late Toxicity. During 
the time interval when most of the aforementioned 
clinical studies were designed and conducted, the 
world of radiation oncology deeply changed. The 
transition from EF-RT to IF-RT was relatively easy 
since IF were “sub-volumes” of EF, and the fields 
delineation was based on the anatomical boundaries 
typical of 2D RT, as exemplified by J. Yahalom and P. 
Mauch in their 2002 classic article.
31
 When CT 
simulation and 3D reconstruction software became 
available, radiation oncologists began to delineate 
smaller involved fields volumes, corresponding to 
a new way of considering IF-RT in comparison 
with the 2D era. At the same time, pre-
chemotherapy imaging (CT and CT-PET) became 
the basis for radiotherapy volumes delineation, 
actually corresponding to involved sites at 
diagnosis. This concept has been recently defined 
as “involved-site radiotherapy” (ISRT), according 
to the HL radiotherapy guidelines, published by 
the International Lymphoma Radiation Oncology 
Group (ILROG),
32
 and was developed on the basis 
of the INRT concept defined by EORTC in H10 
trial.
24
 In both INRT and ISRT, the pre-chemotherapy 
involvement determines the clinical target volume, and 
the resulting irradiated volume is significantly smaller 
than with IFRT. When pre-chemotherapy imaging is 
available, the contouring process could be divided into 
4 steps: 1. delineation of the initially involved 
lymphoma volume on pre-chemotherapy CT (GTV-
CT) as determined by morphology; 2. delineation of 
the initially involved lymphoma volume on pre-
chemotherapy PET/CT (GTV-PET) as determined by 
FDG uptake; 3. pre-chemotherapy PET/CT images co-
registration with post-chemotherapy planning CT scan 
(the GTV-CT and GTV-PET are imported from the 
pre-chemotherapy CT to the post-chemotherapy CT); 
4. delineation of the post-chemotherapy volume using 
the information from both pre-chemotherapy PET and 
pre-chemotherapy CT, taking into account tumor 
shrinkage and other anatomic changes. In this way, a 
CTV is obtained encompassing all the initial 
lymphoma volume while sparing normal tissues that 
were never involved such as lungs, chest wall, muscles 
and mediastinal structures. INRT actually represents a 
special form of ISRT, in which pre-chemotherapy 
imaging is ideal for post-chemotherapy treatment 
planning. Outside clinical trials specifically 
investigating new radiation volumes (i.e. H10 or 
HD17), radiation fields currently used in clinical 
routine (henceforth to be called IS-RT) are 
significantly different from the traditional approach of 
IF-RT. High-quality retrospective clinical data show 
that INRT is safe and effective in terms of disease 
control.
33-35
 
Beyond the IS-RT/IN-RT concept, the technological 
break-troughs in radiation oncology also led to the 
introduction in clinical practice of highly conformal 
techniques such as Intensity Modulated Radiotherapy 
(IMRT). Standard radiation technique consisted in the 
past of simple parallel-opposed anterior-posterior fields 
(AP-PA); also in the era of 3D-conformal radiation 
therapy, the AP-PA approach still represented the most 
classical solution. Reduced and better defined radiation 
volumes, together with the advances in treatment 
planning tools, now allow for the utilization of more 
conformal radiation therapy, based on more consistent 
imaging and advanced radiation delivery techniques. 
As underlined in the ILROG guidelines,
32
 although the 
advantages of IMRT include the tightly conformal 
doses and steep gradient next to normal tissues, target 
definition and treatment delivery verification need even 
more attention than with conventional RT to avoid the 
risk of geographic miss and subsequent decrease in 
tumor control. Image guidance may be required to 
ensure full coverage during the whole treatment; 
preliminary retrospective clinical data on the 
combination of image guidance and IMRT with 
reduced volumes (ISRT) support the safety of this 
approach.
36
 Comparative planning studies showed both 
that INRT may offer a substantial dosimetric benefit in 
comparison with IFRT and that IMRT may result in a 
better dose distribution around the target volumes, 
especially in unfavourable mediastinal presentations 
(bulky disease, involvement of the anterior 
mediastinum).
37-42
 IMRT can also reduce the mean 
dose received by critical thoracic structures such as 
heart and coronary arteries. Figure 1 illustrates an 
example of the dose distribution achievable with 
IMRT, in comparison with 3D-CRT, in a mediastinal 
presentation. The dosimetric gain on healthy tissues 
achievable with IMRT is usually associated with a 
larger amount of normal tissues (for example breasts or 
lungs) receiving very low doses (1-2 Gy out of 30 Gy), 
with a potential negative impact on radiation-induced 
secondary malignancies risk. Historically, the 
shrinkage of radiation fields from EF-RT to IF-RT has 
been shown to decrease the risk of second cancers, as 
reported by De Bruin et al.
43
 This effect might be 
significant also when shifting from IF-RT to ISRT/IN-
RT, especially in specific disease presentations 
(according to the disease extent and the involved 
lymph nodes anatomical location). Few interesting 
modeling studies were conducted with the aim of 
evaluating both the impact of reduced volumes and
Mediterr J Hematol Infect Dis 2014; 6: Open Journal System  
 
 
Figure 1. Involved-site 3D-Conformal Radiotherapy (on the top) vs. Intensity-Modulated Radiotherapy (on the bottom) in a patient 
presenting with Stage IIA mediastinal-supraclavicular Hodgkin’s Lymphoma (Radiation Oncology Department, University of Torino). 
 
IMRT on secondary cancers risk in early stage HL.
44-47
 
Results showed that INRT, at least theoretically, 
reduces the risk of secondary cancers in comparison 
with IFRT; the findings on IMRT vs. 3D-CRT were 
rather unclear, depending on both the IMRT technique 
and the radiobiological models used for risk estimation. 
Valuable clinical data on the incidence of secondary 
tumors after combined modality therapy with INRT-
IMRT will only become available over the next years. 
Table 2 illustrates the time trend in radiotherapy 
volumes/dose/technology evolution since 1960 to 
present. 
 
Conclusions. Early stage HL patients should be 
possibly included in clinical trials investigating for 
treatment optimization. In clinical routine, combined 
modality therapy still represents the standard, with 
radiation oncologists now having the opportunity to 
minimize the risks of late toxicity by using a large 
armada of technological improvements. Long-term 
follow-up is needed to clarify the clinical impact of 
these technical advancements on late morbidity. 
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Table 2. Temporal evolution of radiotherapy for early stage Hodgkin’s lymphoma. 
RT Fields Years Dose 
(Gy) 
Technique Planning Methods Machines 
EFRT 1960-1990 40-44 2D RT 2D planning Cobalt Units; first LINACS 
      
IFRT 1995-2005 30-36 3D-CRT 3D Planning  
Static-IMRT Forward/Inverse planning LINAC with Multileaf Collimator 
      
ISRT/INRT 2005-present 20-30  Static IMRT Inverse Planning LINAC with Multileaf Collimator 
Arc-therapy Biologic Optimization LINAC with Dinamic MLC and 
Image-Guidance 
Tomotherapy Multimodality Imaging Volumetric Modulated Arc 
Therapy 
 Dose Painting Helical Tomotherapy 
 Image-Guided Radiotherapy  
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